ETX Insider Trading

Insider Ownership Percentage: 59.44%
Insider Buying (Last 12 Months): £14,968.60
Insider Selling (Last 12 Months): GBX 0

e-therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at e-therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

e-therapeutics Share Price & Price History

Current Price: GBX 9
Price Change: Price Decrease of -0.65 (-6.74%)
As of 05/8/2024 05:35 PM ET

This chart shows the closing price history over time for ETX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

e-therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2024Trevor Mervyn JonesInsiderBuy91,325GBX 8£7,306
7/6/2023Trevor Mervyn JonesInsiderBuy34,830GBX 22£7,662.60
1/4/2023Trevor Mervyn JonesInsiderBuy44,350GBX 17£7,539.50
7/4/2022Trevor Mervyn JonesInsiderBuy43,913GBX 17£7,465.21
10/26/2021Ali MortazaviInsiderBuy275,000GBX 37£101,750
See Full Table

SEC Filings (Institutional Ownership Changes) for e-therapeutics (LON:ETX)

26.54% of e-therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

e-therapeutics logo
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
Read More on e-therapeutics

Today's Range

Now: GBX 9
Low: 9
High: 10.75

50 Day Range

MA: GBX 10.64
Low: 8.66
High: 12.90

52 Week Range

Now: GBX 9
Low: 8
High: 24

Volume

2,518,125 shs

Average Volume

758,869 shs

Market Capitalization

£52.59 million

P/E Ratio

N/A

Dividend Yield

3.35%

Beta

0.46

Who are the company insiders with the largest holdings of e-therapeutics?

e-therapeutics' top insider investors include:
  1. Trevor Mervyn Jones (Insider)
Learn More about top insider investors at e-therapeutics.